Quarterly ResultAug 13, 2026, 04:20 PM
RenovoRx Q2 Revenue Up 115% to $909K; Net Loss $(2.91)M
AI Summary
RenovoRx reported a significant increase in Q2 2026 revenue, rising 115.4% to $909,000, with gross profit up 183.7% to $766,000. Despite this, the company posted a net loss of $(2.91) million for the quarter and $(6.43) million for the first six months of 2026. RenovoRx also received an additional Orphan Drug Designation for oxaliplatin for pancreatic cancer and initiated a new investigator-initiated trial for cholangiocarcinoma. The company believes its current cash and cash equivalents of $9.5 million are sufficient to fund operations for at least the next 12 months.
Key Highlights
- Q2 2026 revenue increased 115.4% to $909,000 from $422,000 in Q2 2025.
- Q2 2026 gross profit rose 183.7% to $766,000 from $270,000 in Q2 2025.
- Net loss for Q2 2026 was $(2.91) million, compared to $(2.89) million in Q2 2025.
- Cash and cash equivalents stood at $9.48 million as of June 30, 2026.
- Received additional Orphan Drug Designation for oxaliplatin for pancreatic cancer in Q2 2026.
- Began supporting a new IIT study for cholangiocarcinoma in Q2 2026.
- Selling, general and administrative expenses increased 91.5% to $2.92 million in Q2 2026.
Price Impact
More from RNXT